Skip to main content
. Author manuscript; available in PMC: 2013 May 6.
Published in final edited form as: Clin Cancer Res. 2009 Nov 3;15(22):7099–7105. doi: 10.1158/1078-0432.CCR-09-1722

Fig. 1.

Fig. 1

Maximal change in PSA from baseline among 57 CRPC patients treated with KHAD. Y axis is truncated at +100%, but 3 patients had ≥100% increase in PSA from baseline without decline. In total, 9 patients did not have any decline in PSA.